TELA Stock Overview
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy.
TELA Bio Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$8.99|
|52 Week High||US$16.53|
|52 Week Low||US$7.23|
|1 Month Change||-5.37%|
|3 Month Change||-23.49%|
|1 Year Change||-32.15%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-32.66%|
Recent News & Updates
Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
|TELA||US Medical Equipment||US Market|
Return vs Industry: TELA underperformed the US Medical Equipment industry which returned -13% over the past year.
Return vs Market: TELA underperformed the US Market which returned -8.1% over the past year.
|TELA Average Weekly Movement||6.1%|
|Medical Equipment Industry Average Movement||10.6%|
|Market Average Movement||7.8%|
|10% most volatile stocks in US Market||16.9%|
|10% least volatile stocks in US Market||2.9%|
Stable Share Price: TELA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: TELA's weekly volatility (6%) has been stable over the past year.
About the Company
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States.
TELA Bio Fundamentals Summary
|TELA fundamental statistics|
Is TELA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|TELA income statement (TTM)|
|Cost of Revenue||US$11.17m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-2.47|
|Net Profit Margin||-113.15%|
How did TELA perform over the long term?See historical performance and comparison
Is TELA Bio undervalued compared to its fair value and its price relative to the market?
Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TELA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TELA's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: TELA is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.
PE vs Market: TELA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TELA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TELA is overvalued based on its PB Ratio (13x) compared to the US Medical Equipment industry average (2.5x).
How is TELA Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TELA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TELA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TELA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TELA's revenue (25.9% per year) is forecast to grow faster than the US market (7.8% per year).
High Growth Revenue: TELA's revenue (25.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if TELA's Return on Equity is forecast to be high in 3 years time
How has TELA Bio performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TELA is currently unprofitable.
Growing Profit Margin: TELA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TELA is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare TELA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TELA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (16.1%).
Return on Equity
High ROE: TELA has a negative Return on Equity (-358.66%), as it is currently unprofitable.
How is TELA Bio's financial position?
Financial Health Score3/6
Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: TELA's short term assets ($50.3M) exceed its short term liabilities ($12.3M).
Long Term Liabilities: TELA's short term assets ($50.3M) exceed its long term liabilities ($33.0M).
Debt to Equity History and Analysis
Debt Level: TELA has more cash than its total debt.
Reducing Debt: Insufficient data to determine if TELA's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TELA has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: TELA has less than a year of cash runway if free cash flow continues to reduce at historical rates of 9.7% each year
What is TELA Bio current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TELA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TELA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TELA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TELA's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TELA has not reported any payouts.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Antony Koblish (55 yo)
Mr. Antony Koblish is an Operating Partner of 1315 Capital LLC. Mr. Koblish serves as the President, Director and Chief Executive Officer of TELA Bio, Inc. since April 2012, which he co-founded in April 20...
CEO Compensation Analysis
Compensation vs Market: Antony's total compensation ($USD2.11M) is above average for companies of similar size in the US market ($USD771.97K).
Compensation vs Earnings: Antony's compensation has increased whilst the company is unprofitable.
Experienced Management: TELA's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: TELA's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
TELA Bio, Inc.'s employee growth, exchange listings and data sources
- Name: TELA Bio, Inc.
- Ticker: TELA
- Exchange: NasdaqGM
- Founded: 2012
- Industry: Health Care Supplies
- Sector: Healthcare
- Implied Market Cap: US$130.872m
- Shares outstanding: 14.56m
- Website: https://www.telabio.com
Number of Employees
- TELA Bio, Inc.
- 1 Great Valley Parkway
- Suite 24
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/18 00:00|
|End of Day Share Price||2022/05/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.